Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cardiovascular Disorders
Published in: BMC Cardiovascular Disorders 1/2016

Open Access 01-12-2016 | Research article

Adipo/cytokines in atherosclerotic secretomes: increased visfatin levels in unstable carotid plaque

Authors: Teresa Auguet, Gemma Aragonès, Esther Guiu-Jurado, Alba Berlanga, Marta Curriu, Salomé Martinez, Ajla Alibalic, Carmen Aguilar, María-Luisa Camara, Esteban Hernández, Xavier Ruyra, Vicente Martín-Paredero, Cristóbal Richart

Published in: BMC Cardiovascular Disorders | Issue 1/2016

Login to get access

Abstract

Background

Novel pro-inflammatory and anti-inflammatory derivatives from adipose tissue, known as adipokines, act as metabolic factors. The aim of this study was to analyse the secreted expression of different adipo/cytokines in secretomes of unstable carotid atherosclerotic plaque versus non-atherosclerotic mammary artery.

Methods

We evaluated the secretion levels of adiponectin, visfatin, lipocalin-2, resistin, IL-6 and TNFR2 by ELISA in human secretomes from cultured unstable carotid atherosclerotic plaque (n = 18) and non-atherosclerotic mammary artery (n = 13). We also measured visfatin serum levels in patients suffering from atherosclerosis and in a serum cohort of healthy subjects (n = 16).

Results

We found that visfatin levels were significantly increased in unstable carotid atherosclerotic plaque secretome than in non-atherosclerotic mammary artery secretome. No differences were found with regard the other adipo/cytokines studied. Regarding visfatin circulating levels, there were no differences between unstable carotid atherosclerotic plaque and non-atherosclerotic mammary artery group. However, these visfatin levels were increased in comparison to serum cohort of healthy subjects.

Conclusions

Of all the adipo/cytokines analysed, only visfatin showed increased levels in secretomes of unstable carotid atherosclerotic plaque. Additional human studies are needed to clarify the possible role of visfatin as prognostic factor of unstable carotid atherosclerotic plaque.
Literature
1.
Sahin-Efe A, Katsikeris F, Mantzoros CS. Advances in adipokines. Metabolism. 2012;61(12):1659–65.CrossRefPubMed
2.
Chang L, Milton H, Eitzman DT, Chen YE. Paradoxical roles of perivascular adipose tissue in atherosclerosis and hypertension. Circ J. 2012;77(1):11–8.CrossRefPubMed
3.
4.
Van de Voorde J, Pauwels B, Boydens C, Decaluwé K. Adipocytokines in relation to cardiovascular disease. Metabolism. 2013;62(11):1513–21.CrossRefPubMed
5.
Mattu HS, Randeva HS. Role of adipokines in cardiovascular disease. J Endocrinol. 2013;216(1):T17–36.CrossRefPubMed
6.
Ntaios G, Gatselis NK, Makaritsis K, Dalekos GN. Adipokines as mediators of endothelial function and atherosclerosis. Atherosclerosis. 2013;227(2):216–21.CrossRefPubMed
7.
Anfossi G, Russo I, Doronzo G, Pomero A, Trovati M. Adipocytokines in atherothrombosis: focus on platelets and vascular smooth muscle cells. Mediators Inflamm. 2010;2010:174341.CrossRefPubMedPubMedCentral
8.
Schneiderman J, Simon AJ, Schroeter MR, Flugelman MY, Konstantinides S, Schaefer K. Leptin receptor is elevated in carotid plaques from neurologically symptomatic patients and positively correlated with augmented macrophage density. J Vasc Surg. 2008;48(5):1146–55.CrossRefPubMed
9.
Cho Y, Lee SE, Lee HC, Hur J, Lee S, Youn SW, et al. Adipokine resistin is a key player to modulate monocytes, endothelial cells, and smooth muscle cells, leading to progression of atherosclerosis in rabbit carotid artery. J Am Coll Cardiol. 2011;57(1):99–109.CrossRefPubMed
10.
De la Cuesta F, Barderas MG, Calvo E, Zubiri I, Maroto AS, Darde VM, et al. Secretome analysis of atherosclerotic and non-atherosclerotic arteries reveals dynamic extracellular remodeling during pathogenesis. J Proteomics. 2012;75(10):2960–71.CrossRefPubMed
11.
Stary HC. Natural history and histological classification of atherosclerotic lesions: an update. Arterioscler Thromb Vasc Biol. 2000;20(5):1177–78.CrossRefPubMed
12.
Terra X, Auguet T, Broch M, Sabench F, Hernández M, Pastor RM, et al. Retinol binding protein-4 circulating levels were higher in nonalcoholic fatty liver disease vs. histologically normal liver from morbidly obese women. Obesity (Silver Spring). 2013;21(1):170–7.CrossRef
13.
Durán MC, Martín-Ventura JL, Mas S, Barderas MG, Dardé VM, Jensen ON, et al. Characterization of the human atheroma plaque secretome by proteomic analysis. Methods Mol Biol. 2007;357:141–50.PubMed
14.
Kato A, Odamaki M, Ishida J, Hishida A. Relationship between serum pre-B cell colony-enhancing factor/Visfatin and atherosclerotic parameters in chronic hemodialysis patients. Am J Nephrol. 2009;29(1):31–5.CrossRefPubMed
15.
Chen MP, Chung FM, Chang DM, Tsai JC, Huang HF, Shin SJ, et al. Elevated plasma level of Visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2006;91(1):295–9.CrossRefPubMed
16.
Goktas Z, Owens S, Boylan M, Syn D, Shen CL, Reed DB, et al. Associations between tissue visfatin/nicotinamide, phosphoribosyltransferase (Nampt), retinol binding protein-4, and vaspin concentrations and insulin resistance in morbidly obese subjects. Mediators Inflamm. 2013;2013:861496.CrossRefPubMedPubMedCentral
17.
Filippatos TD, Derdemezis CS, Gazi IF, Lagos K, Kiortsis DN, Tselepis AD, et al. Increased plasma visfatin levels in subjects with the metabolic syndrome. Eur J Clin Invest. 2008;38(1):71–2.CrossRefPubMed
18.
Ahmed MB, Ismail MI, Meki AR. Relation of osteoprotegerin, visfatin and ghrelin to metabolic syndrome in type 2 diabetic patients. Int J Health Sci (Qassim). 2015;9(2):127–39.
19.
Romacho T, Sánchez-Ferrer CF, Peiró C. Visfatin/Nampt: an adipokine with cardiovascular impact. Mediators Inflamm. 2013;2013:946427S.CrossRef
20.
Liu SW, Qiao SB, Yuan JS, Liu DQ. Association of plasma visfatin levels with inflammation, atherosclerosis, and acute coronary syndromes in humans. Clin Endocrinol (Oxf). 2009;71(2):202–7.CrossRef
21.
Kong Q, Xia M, Liang R, Li L, Cu X, Sun Z, et al. Increased serum visfatin as a risk factor for atherosclerosis in patients with ischaemic cerebrovascular disease. Singapore Med J. 2014;55(7):383–87.CrossRefPubMedPubMedCentral
22.
Dahl TB, Yndestad A, Skjelland M, Øie E, Dahl A, Michelsen A, et al. Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization. Circulation. 2007;115(8):972–80.CrossRefPubMed
23.
Zhou F, Pan Y, Huang Z, Jia Y, Zhao X, Chen Y, et al. Visfatin induces cholesterol accumulation in macrophages through up-regulation of scavenger receptor-A and CD36. Cell Stress Chaperones. 2013;18(5):643–52.CrossRefPubMedPubMedCentral
24.
Chiu CA, Yu TH, Hung WC. Increased expression of visfatin in monocytes and macrophages in male acute myocardial infarction patients. Mediators Inflamm. 2012;2012:469852.CrossRefPubMedPubMedCentral
25.
Yamawaki H, Hara N, Okada M, Hara Y. Visfatin causes endothelium-dependent relaxation in isolated blood vessels. Biochem Biophys Res Commun. 2009;383(4):503–8.CrossRefPubMed
26.
Kim SR, Bae SK, Choi KS, Park SY, Jun HO, Lee JY, et al. Visfatin promotes angiogenesis by activation of extracellular signal-regulated kinase 1/2. Biochem Biophys Res Commun. 2007;357(1):150–6.CrossRefPubMed
27.
Vallejo S, Romacho T, Angulo J, Villalobos LA, Cercas E, Leivas A. Visfatin impairs endothelium-dependent relaxation in rat and human mesenteric microvessels through nicotinamide phosphoribosyltransferase activity. PLoS One. 2011;6(11):e27299.CrossRefPubMedPubMedCentral
28.
Takebayashi K, Suetsugu M, Wakabayashi S, Aso Y, Inukai T. Association between plasma visfatin and vascular endothelial function in patients with type 2 diabetes mellitus. Metabolism. 2007;56:451–8.CrossRefPubMed
29.
Dahl T, Ranheim T, Holm S, Berge R, Aukrust P, Halvorsen P. Nicotinamide phosphoribosyltransferase and lipid accumulation in macrophages. Eur J Clin Invest. 2011;41(10):1098–104.CrossRefPubMed
30.
Fonseca DA, Antunes PE, Cotrim MD. Endothelium-dependent vasoactivity of the human internal mammary artery. Coron Artery Dis. 2014;25(3):266–74.PubMed
31.
Otsuka F, Yahagi K, Sakakura K, Virmani R. Why is the mammary artery so special and what protects it from atherosclerosis? Ann Cardiothorac Surg. 2013;2(4):519–26.PubMedPubMedCentral
32.
Lu YC, Hsu CC, Yu TH, Wang CP, Lu LF, Hung WC, et al. Association between visfatin levels and coronary artery disease in patients with chronic kidnay disease. Iran J Kidney Dis. 2013;7(6):446–52.PubMed
33.
Tang X, Chen M, Zhang W. Association between elevated visfatin and carotid atherosclerosis in patients with chronic kidney disease. J Cent South Univ (Med Sci). 2013;38(6):553–9.
34.
Hung WC, Yu TH, Hsu CC, Lu LF, Chung FM, Tsai IT, et al. Plasma visfatin levels are associated with major adverse cardiovascular events in patients with acute ST-elevation myocardial infarction. Clin Invest Med. 2015;38(3):E100–9.PubMed
35.
Luo N, Liu J, Chung BH, Yang Q, Klein RL, Garvey WT, et al. Macrophage adiponectin expression improves insulin sensitivity and protects against inflammation and atherosclerosis. Diabetes. 2010;59(4):791–9.CrossRefPubMedPubMedCentral
36.
Puz P, Lasek-Bal A, Ziaja D, Kazibutowska Z, Ziaja K. Inflammatory markers in patients with internal carotid artery stenosis. Arch Med Sci. 2013;9(2):254–60.CrossRefPubMedPubMedCentral
Metadata
Title
Adipo/cytokines in atherosclerotic secretomes: increased visfatin levels in unstable carotid plaque
Authors
Teresa Auguet
Gemma Aragonès
Esther Guiu-Jurado
Alba Berlanga
Marta Curriu
Salomé Martinez
Ajla Alibalic
Carmen Aguilar
María-Luisa Camara
Esteban Hernández
Xavier Ruyra
Vicente Martín-Paredero
Cristóbal Richart
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Cardiovascular Disorders / Issue 1/2016
Electronic ISSN: 1471-2261
DOI
https://doi.org/10.1186/s12872-016-0320-5

Other articles of this Issue 1/2016

BMC Cardiovascular Disorders 1/2016 Go to the issue

Research article

The relationship between sodium excretion and blood pressure, urine albumin, central retinal arteriolar equivalent

Research article

Impact of impaired fractional flow reserve after coronary interventions on outcomes: a systematic review and meta-analysis

Research article

Influence of smoking cessation drugs on blood pressure and heart rate in patients with cardiovascular disease or high risk score: real life setting

Research article

Clinical assessment of patients with chest pain; a systematic review of predictive tools

Research article

Oral anticoagulation with vitamin K inhibitors and determinants of successful self-management in primary care

Research article

Primary skeletal muscle myoblasts from chronic heart failure patients exhibit loss of anti-inflammatory and proliferative activity

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits